{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:57:35Z","timestamp":1790643455310,"version":"4.1.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Pharvaris"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03790-2","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T07:43:28Z","timestamp":1790581408000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient Experience with Treatment of HAE Attacks: Results from a Real-World Survey of Physicians and Their Patients"],"prefix":"10.1007","author":[{"given":"John","family":"Anderson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Bouillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula J.","family":"Busse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Caballero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Guilarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiro","family":"Hide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"Lleonart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Lumry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Magerl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Riedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick F. K.","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Zanichelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1139-0078","authenticated-orcid":false,"given":"Joan","family":"Mendivil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"3790_CR1","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.anai.2020.02.018","volume":"124","author":"A Banerji","year":"2020","unstructured":"Banerji A, Davis KH, Brown TM, et al. Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States. Ann Allergy Asthma Immunol. 2020;124:600\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3790_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-021-00537-2","volume":"17","author":"K Bork","year":"2021","unstructured":"Bork K, Anderson JT, Caballero T, et al. Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report. Allergy Asthma Clin Immunol. 2021;17:40.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"3790_CR3","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s12016-016-8575-2","volume":"51","author":"H Longhurst","year":"2016","unstructured":"Longhurst H, Bygum A. The humanistic, societal, and pharmaco-economic burden of angioedema. Clin Rev Allergy Immunol. 2016;51:230\u20139.","journal-title":"Clin Rev Allergy Immunol"},{"key":"3790_CR4","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.2500\/aap.2020.41.200050","volume":"41","author":"WR Lumry","year":"2020","unstructured":"Lumry WR, Settipane RA. Hereditary angioedema: epidemiology and burden of disease. Allergy Asthma Proc. 2020;41:S8-13.","journal-title":"Allergy Asthma Proc"},{"key":"3790_CR5","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1808012","volume":"382","author":"PJ Busse","year":"2020","unstructured":"Busse PJ, Christiansen SC. Hereditary angioedema. N Engl J Med. 2020;382:1136\u201348.","journal-title":"N Engl J Med"},{"key":"3790_CR6","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jaip.2020.08.046","volume":"9","author":"PJ Busse","year":"2021","unstructured":"Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9:132-50.e3.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"3790_CR7","doi-asserted-by":"publisher","first-page":"391","DOI":"10.12968\/hmed.2019.80.7.391","volume":"80","author":"HJ Longhurst","year":"2019","unstructured":"Longhurst HJ, Bork K. Hereditary angioedema: an update on causes, manifestations and treatment. Br J Hosp Med (Lond). 2019;80:391\u20138.","journal-title":"Br J Hosp Med (Lond)"},{"key":"3790_CR8","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1111\/all.15214","volume":"77","author":"M Maurer","year":"2022","unstructured":"Maurer M, Magerl M, Betschel S, et al. The international WAO\/EAACI guideline for the management of hereditary angioedema\u2014the 2021 revision and update. Allergy. 2022;77:1961\u201390.","journal-title":"Allergy"},{"key":"3790_CR9","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1159\/000543321","volume":"186","author":"SA Fisch","year":"2025","unstructured":"Fisch SA, Rundle AG, Neugut AI, Freedberg DE. Worldwide prevalence of hereditary angioedema: a systematic review and meta-analysis. Int Arch Allergy Immunol. 2025;186:802\u201310.","journal-title":"Int Arch Allergy Immunol"},{"key":"3790_CR10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s12016-021-08854-5","volume":"61","author":"AK Jindal","year":"2021","unstructured":"Jindal AK, Reshef A, Longhurst H, Global Equity in HAE Management working group. Mitigating disparity in health-care resources between countries for management of hereditary angioedema. Clin Rev Allergy Immunol. 2021;61:84\u201397.","journal-title":"Clin Rev Allergy Immunol"},{"key":"3790_CR11","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.jaip.2022.12.021","volume":"11","author":"PH Li","year":"2023","unstructured":"Li PH, Pawankar R, Thong BY, et al. Epidemiology, management, and treatment access of hereditary angioedema in the Asia Pacific region: outcomes from an international survey. J Allergy Clin Immunol Pract. 2023;11:1253\u201360.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"3790_CR12","unstructured":"US Food and Drug Administration. Takhzyro prescribing information. https:\/\/www.shirecontent.com\/PI\/PDFs\/TAKHZYRO_USA_ENG.pdf. Accessed April 16, 2026."},{"key":"3790_CR13","unstructured":"US Food and Drug Administration. Orladeyo prescribing information. https:\/\/www.biocryst.com\/wp-content\/uploads\/sites\/13\/2025\/12\/ORLADEYO_USPI.pdf. Accessed April 16, 2026."},{"key":"3790_CR14","unstructured":"US Food and Drug Administration. Haegarda prescribing information. https:\/\/labeling.cslbehring.com\/PI\/US\/HAEGARDA\/EN\/HAEGARDA-Prescribing-Information.pdf. Accessed April 16, 2026."},{"key":"3790_CR15","unstructured":"US Food and Drug Administration. Dawnzera prescribing information. https:\/\/ionis.com\/medicines\/DAWNZERA\/DAWNZERA-FPI.pdf. Accessed April 16, 2026."},{"key":"3790_CR16","unstructured":"US Food and Drug Administration. Cinryze prescribing information https:\/\/pi.shirecontent.com\/PI\/PDFs\/Cinryze_USA_ENG.pdf. Accessed April 16, 2026."},{"key":"3790_CR17","unstructured":"US Food and Drug Administration. Ekterly prescribing information. https:\/\/www.kalvista.com\/ekterly-us-prescribing-information.pdf. Accessed April 16, 2026."},{"key":"3790_CR18","unstructured":"US Food and Drug Administration. Berinert prescribing information. https:\/\/labeling.cslbehring.com\/pi\/us\/berinert\/en\/berinert-prescribing-information.pdf. Accessed April 16, 2026."},{"key":"3790_CR19","unstructured":"US Food and Drug Administration. Firazyr prescribing information. https:\/\/www.shirecontent.com\/PI\/PDFs\/Firazyr_USA_ENG.pdf. Accessed April 16, 2026."},{"key":"3790_CR20","unstructured":"US Food and Drug Administration. Kalbitor prescribing information. https:\/\/www.shirecontent.com\/PI\/PDFs\/Kalbitor_USA_ENG.pdf. Accessed April 16, 2026."},{"key":"3790_CR21","unstructured":"US Food and Drug Administration. Ruconest prescribing information. https:\/\/www.ruconest.com\/wp-content\/uploads\/Ruconest_PI_Apr2020.pdf. Accessed April 16, 2026."},{"key":"3790_CR22","unstructured":"US Food and Drug Administration. Andembry prescribing information. https:\/\/labeling.cslbehring.com\/PI\/US\/Andembry\/EN\/Andembry-Prescribing-Information.pdf. Accessed April 16, 2026."},{"key":"3790_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-024-00903-w","volume":"20","author":"SD Betschel","year":"2024","unstructured":"Betschel SD, Caballero T, Jones DH, et al. The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks. Allergy Asthma Clin Immunol. 2024;20:43.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"3790_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-025-00969-0","volume":"21","author":"SD Betschel","year":"2025","unstructured":"Betschel SD, Peter J, Lumry W, et al. Factors contributing to non-compliance with on-demand treatment guidelines in hereditary angioedema. Allergy Asthma Clin Immunol. 2025;21:25.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"3790_CR25","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.anai.2024.12.012","volume":"134","author":"S Christiansen","year":"2025","unstructured":"Christiansen S, O\u2019Connor M, Craig T, et al. On-demand treatment of hereditary angioedema attacks: patient-reported utilization, barriers, and outcomes. Ann Allergy Asthma Immunol. 2025;134:570-9.e4.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3790_CR26","unstructured":"European Medicines Agency. Orladeyo summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/orladeyo-epar-product-information_en.pdf. Accessed April 16, 2026."},{"key":"3790_CR27","unstructured":"BioCryst. BioCryst announces approval of ORLADEYO\u00ae (berotralstat) in Saudi Arabia. https:\/\/ir.biocryst.com\/news-releases\/news-release-details\/biocryst-announces-approval-orladeyor-berotralstat-saudi-arabia. Accessed April 16, 2026."},{"key":"3790_CR28","unstructured":"BioCryst. BioCryst announces approval of ORLADEYO\u2122 (berotralstat) in Japan for the prophylactic treatment of hereditary angioedema. https:\/\/ir.biocryst.com\/news-releases\/news-release-details\/biocryst-announces-approval-orladeyotm-berotralstat-japan. Accessed April 16, 2026."},{"key":"3790_CR29","unstructured":"European Medicines Agency. Ekterly summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ekterly-epar-product-information_en.pdf. Accessed April 16, 2026."},{"key":"3790_CR30","unstructured":"Medicines and Healthcare products Regulatory Agency (United Kingdom). Ekterly summary of product characteristics. https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/39e60ef58d77f096e4b09b5a9558458a04d6d0f9. Accessed April 16, 2026."},{"key":"3790_CR31","unstructured":"Therapeutic Goods Administration. Ekterly (sebetralstat) Australian prescription medicine decision summary. https:\/\/www.tga.gov.au\/resources\/auspmd\/ekterly-sebetralstat. Accessed April 16, 2026."},{"key":"3790_CR32","unstructured":"Health Sciences Authority Register of Therapeutic Products. Government of Singapore. Ekterly package insert. Registration No. SIN17392P. http:\/\/eservice.hsa.gov.sg\/prism\/common\/enquirepublic\/SearchDRBProduct.do?action=load. Accessed April 16, 2026."},{"key":"3790_CR33","unstructured":"KalVista. KalVista Pharmaceuticals announces approval of EKTERLY\u00ae (sebetralstat) in Japan, first and only oral on-demand treatment for hereditary angioedema. https:\/\/ir.kalvista.com\/news-releases\/news-release-details\/kalvista-pharmaceuticals-announces-approval-ekterlyr. Accessed April 16, 2026."},{"key":"3790_CR34","unstructured":"ClinicalTrials.gov. NCT04618211. Dose-ranging study of oral PHA-022121 for acute treatment of angioedema attacks in patients with hereditary angioedema (RAPIDe-1). https:\/\/www.clinicaltrials.gov\/study\/NCT04618211. Accessed April 16, 2026."},{"key":"3790_CR35","unstructured":"ClinicalTrials.gov. NCT05396105. Extension study of oral PHA-022121 for acute treatment of angioedema attacks in patients with hereditary angioedema (RAPIDe-2). https:\/\/clinicaltrials.gov\/study\/NCT05396105. Accessed April 16, 2026."},{"key":"3790_CR36","unstructured":"ClinicalTrials.gov. NCT06343779. Study of oral deucrictibant soft capsule for on-demand treatment of angioedema attacks in adolescents and adults with hereditary angioedema (RAPIDe-3). https:\/\/www.clinicaltrials.gov\/study\/NCT06343779. Accessed April 16, 2026."},{"key":"3790_CR37","unstructured":"ClinicalTrials.gov. NCT05047185. Dose-ranging study of oral PHA-022121 for prophylaxis against angioedema attacks in patients with hereditary angioedema type I or type II (HAE CHAPTER-1). https:\/\/www.clinicaltrials.gov\/study\/NCT05047185. Accessed April 16, 2026."},{"key":"3790_CR38","unstructured":"ClinicalTrials.gov. NCT06669754. Study of oral deucrictibant extended-release tablet for prophylaxis against angioedema attacks in adolescents and adults with HAE (CHAPTER-3). https:\/\/clinicaltrials.gov\/study\/NCT06669754. Accessed April 16, 2026."},{"key":"3790_CR39","unstructured":"ClinicalTrials.gov. NCT06679881. Long-term, open-label study of oral deucrictibant extended-release tablet for prophylaxis against angioedema attacks in adolescents and adults with HAE (CHAPTER-4). https:\/\/clinicaltrials.gov\/study\/NCT06679881. Accessed April 16, 2026."},{"key":"3790_CR40","first-page":"S31","volume":"135","author":"J Anderson","year":"2025","unstructured":"Anderson J, Ayg\u00f6ren-P\u00fcrs\u00fcn E, Farkas H, et al. Long-term safety and efficacy of oral deucrictibant for treatment of hereditary angioedema attacks: RAPIDe-2 results. Ann Allergy Asthma Immunol. 2025;135:S31\u20132.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3790_CR41","unstructured":"Anderson J, Ayg\u00f6ren-P\u00fcrs\u00fcn E, Farkas H, et al. Outcomes of deucrictibant-treated upper airway and laryngeal hereditary angioedema attacks: RAPIDe-2 Part A results. https:\/\/ir.pharvaris.com\/static-files\/efda4396-1f60-4e46-b367-f2422c7db533. Accessed April 16, 2026."},{"key":"3790_CR42","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-025-09132-4","volume":"69","author":"J Mendivil","year":"2026","unstructured":"Mendivil J, Zhu L, Bonner N, et al. Assessing patient-reported outcomes in acute attacks of hereditary angioedema: insights from a mixed methods study of participants receiving standard-of-care treatments in a real-world setting. Clin Rev Allergy Immunol. 2026;69:14.","journal-title":"Clin Rev Allergy Immunol"},{"key":"3790_CR43","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1016\/S2352-3026(25)00341-2","volume":"13","author":"M Maurer","year":"2026","unstructured":"Maurer M, Stobiecki M, Valerieva A, et al. Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Haematol. 2026;13:e200\u201314.","journal-title":"Lancet Haematol"},{"key":"3790_CR44","doi-asserted-by":"publisher","first-page":"e215","DOI":"10.1016\/S2352-3026(26)00004-9","volume":"13","author":"E Ayg\u00f6ren-P\u00fcrs\u00fcn","year":"2026","unstructured":"Ayg\u00f6ren-P\u00fcrs\u00fcn E, Stobiecki M, Valerieva A, et al. Oral deucrictibant for prophylaxis of hereditary angioedema attacks (CHAPTER-1): primary analysis of a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Haematol. 2026;13:e215\u201326.","journal-title":"Lancet Haematol"},{"key":"3790_CR45","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1056\/NEJMoa2405734","volume":"392","author":"DM Cohn","year":"2025","unstructured":"Cohn DM, Gurugama P, Magerl M, et al. CRISPR-based therapy for hereditary angioedema. N Engl J Med. 2025;392:458\u201367.","journal-title":"N Engl J Med"},{"key":"3790_CR46","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/NEJMoa2309149","volume":"390","author":"HJ Longhurst","year":"2024","unstructured":"Longhurst HJ, Lindsay K, Petersen RS, et al. CRISPR-Cas9 in vivo gene editing of KLKB1 for hereditary angioedema. N Engl J Med. 2024;390:432\u201341.","journal-title":"N Engl J Med"},{"key":"3790_CR47","unstructured":"ClinicalTrials.gov. NCT06960213. STOP-HAE: a phase 3 study of ADX-324 in HAE (STOP-HAE). https:\/\/clinicaltrials.gov\/study\/NCT06960213. Accessed April 16, 2026."},{"key":"3790_CR48","unstructured":"ClinicalTrials.gov. NCT05691361. Safety, tolerability, PK, PD of ADX-324 in healthy volunteers and hereditary angioedema patients. https:\/\/clinicaltrials.gov\/study\/NCT05691361. Accessed April 16, 2026."},{"key":"3790_CR49","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.anai.2025.03.016","volume":"135","author":"W Lumry","year":"2025","unstructured":"Lumry W, Gunsior M, Cohen T, et al. Safety and pharmacokinetics of long-acting plasma kallikrein inhibitor navenibart (STAR-0215) in healthy adults. Ann Allergy Asthma Immunol. 2025;135:103-11.e2.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3790_CR50","doi-asserted-by":"publisher","first-page":"5879","DOI":"10.1007\/s12325-025-03382-6","volume":"42","author":"K Uminski","year":"2025","unstructured":"Uminski K, Goodyear D, Betschel S. Therapeutic advances in hereditary angioedema: a focus on present and future options. Adv Ther. 2025;42:5879\u201395.","journal-title":"Adv Ther"},{"key":"3790_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-025-00999-8","volume":"22","author":"S Betschel","year":"2026","unstructured":"Betschel S, Binkley K, Borici-Mazi R, et al. The international\/Canadian hereditary angioedema guideline. Allergy Asthma Clin Immunol. 2026;22:24.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"3790_CR52","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1016\/j.anai.2020.08.095","volume":"125","author":"M Riedl","year":"2020","unstructured":"Riedl M, Craig T, Banerji A, et al. Understanding differences in perceptions of hereditary angioedema treatment burden may improve patient-physician treatment care dialogue. Ann Allergy Asthma Immunol. 2020;125:S24-25.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3790_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0329585","volume":"20","author":"EL Langmack","year":"2025","unstructured":"Langmack EL, Ravyn D, Lowney R, Goodwin B, Lumry WR. Barriers and promoters to adapting research findings to clinical care in hereditary angioedema in the United States: a qualitative study. PLoS ONE. 2025;20:e0329585.","journal-title":"PLoS ONE"},{"key":"3790_CR54","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/j.anai.2025.08.126","volume":"135","author":"P Busse","year":"2025","unstructured":"Busse P, Wilson K, Farkas H, et al. Barriers to achieving normalization among people living with HAE on existing treatments. Ann Allergy Asthma Immunol. 2025;135:S38-9.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3790_CR55","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: disease-specific programmes \u2013 a means to understand. Curr Med Res Opin. 2008;24:3063\u201372.","journal-title":"Curr Med Res Opin"},{"key":"3790_CR56","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1080\/03007995.2023.2279679","volume":"39","author":"P Anderson","year":"2023","unstructured":"Anderson P, Higgins V, de Courcy J, et al. Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: an update on disease specific programmes. Curr Med Res Opin. 2023;39:1707\u201315.","journal-title":"Curr Med Res Opin"},{"key":"3790_CR57","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010352","volume":"6","author":"SM Babineaux","year":"2016","unstructured":"Babineaux SM, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the disease specific programme. BMJ Open. 2016;6:e010352.","journal-title":"BMJ Open"},{"key":"3790_CR58","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2147\/DMSO.S120101","volume":"9","author":"V Higgins","year":"2016","unstructured":"Higgins V, Piercy J, Roughley A, et al. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes. 2016;9:371\u201380.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"3790_CR59","unstructured":"EuroQol Group. EQ-5D-5L. https:\/\/euroqol.org\/information-and-support\/euroqol-instruments\/eq-5d-5l\/. Accessed April 16, 2026."},{"key":"3790_CR60","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1111\/all.12007","volume":"67","author":"K Weller","year":"2012","unstructured":"Weller K, Groffik A, Magerl M, et al. Development and construct validation of the angioedema quality of life questionnaire. Allergy. 2012;67:1289\u201398.","journal-title":"Allergy"},{"key":"3790_CR61","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4:353\u201365.","journal-title":"Pharmacoeconomics"},{"key":"3790_CR62","unstructured":"Reilly Associates. WPAI:SHP V2.0. http:\/\/www.reillyassociates.net\/wpai_shp.html. Accessed April 16, 2026."},{"key":"3790_CR63","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.amjmed.2005.09.064","volume":"119","author":"K Bork","year":"2006","unstructured":"Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med. 2006;119:267\u201374.","journal-title":"Am J Med"},{"key":"3790_CR64","volume-title":"StatPearls","author":"A Abdulkarim","year":"2023","unstructured":"Abdulkarim A, Craig TJ. Hereditary angioedema. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023."},{"key":"3790_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2025.101100","volume":"18","author":"H Farkas","year":"2025","unstructured":"Farkas H, Ayg\u00f6ren-P\u00fcrs\u00fcn E, Ebo DG, et al. Real-world treatment patterns and burden-of-disease of sub-optimally controlled hereditary angioedema. World Allergy Organ J. 2025;18:101100.","journal-title":"World Allergy Organ J"},{"key":"3790_CR66","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1016\/j.jaip.2023.03.006","volume":"11","author":"NS Arora","year":"2023","unstructured":"Arora NS, Nelson B, Carpenter L, et al. Consequences of insurance coverage delays and denials for patients with hereditary angioedema. J Allergy Clin Immunol Pract. 2023;11:2432-8.e1.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"3790_CR67","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.anai.2023.03.005","volume":"130","author":"JA Meadows","year":"2023","unstructured":"Meadows JA, Anderson J, Gower RG. Challenges in the management of hereditary angioedema in urban and rural settings: results of a United States survey. Ann Allergy Asthma Immunol. 2023;130:760-7.e3.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3790_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ienj.2023.101339","volume":"71","author":"AE Burton","year":"2023","unstructured":"Burton AE, Lindsay-Wiles I, Herron D, et al. Hereditary angioedema patient experiences of medication use and emergency care. Int Emerg Nurs. 2023;71:101339.","journal-title":"Int Emerg Nurs"},{"key":"3790_CR69","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.2500\/aap.2021.42.210025","volume":"42","author":"C Radojicic","year":"2021","unstructured":"Radojicic C, Riedl MA, Craig TJ, et al. Patient perspectives on the treatment burden of injectable medication for hereditary angioedema. Allergy Asthma Proc. 2021;42:S4-10.","journal-title":"Allergy Asthma Proc"},{"key":"3790_CR70","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.anai.2017.05.017","volume":"119","author":"MA Riedl","year":"2017","unstructured":"Riedl MA, Banerji A, Busse PJ, et al. Patient satisfaction and experience with intravenously administered C1-inhibitor concentrates in the United States. Ann Allergy Asthma Immunol. 2017;119:59\u201364.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3790_CR71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0260805","volume":"16","author":"G Jain","year":"2021","unstructured":"Jain G, Walter L, Reed C, O\u2019Donnell P, Troy J. How do patients and physicians communicate about hereditary angioedema in the United States? PLoS ONE. 2021;16:e0260805.","journal-title":"PLoS ONE"},{"issue":"1","key":"3790_CR72","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13223-021-00550-5","volume":"17","author":"J Anderson","year":"2021","unstructured":"Anderson J, Levy DS, Lumry W, Koochaki P, Lanar S, Henry Li H. Letting the patients speak: an in-depth, qualitative research-based investigation of factors relevant to health-related quality of life in real-world patients with hereditary angioedema using subcutaneous C1 inhibitor replacement therapy. Allergy Asthma Clin Immunol. 2021;17:60.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"3790_CR73","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1016\/j.jaip.2021.04.072","volume":"9","author":"T Buttgereit","year":"2021","unstructured":"Buttgereit T, Vera C, Weller K, et al. Lanadelumab efficacy, safety, and injection interval extension in HAE: a real-life study. J Allergy Clin Immunol Pract. 2021;9:3744\u201351.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"3790_CR74","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.anai.2023.10.011","volume":"132","author":"AP Baptist","year":"2024","unstructured":"Baptist AP, Freigeh GE, Nelson B, et al. Hereditary angioedema in older adults: understanding the patient perspective. Ann Allergy Asthma Immunol. 2024;132:76-81.e2.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3790_CR75","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/21556660.2020.1863699","volume":"10","author":"D Geba","year":"2021","unstructured":"Geba D, Mohd Sani J, Gascon M, Hahn R, Aggarwal K, Rosselli J. Hereditary angioedema patients would prefer newer-generation oral prophylaxis. J Drug Assess. 2021;10:51\u20136.","journal-title":"J Drug Assess"},{"key":"3790_CR76","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.2500\/aap.2021.42.210017","volume":"42","author":"MA Riedl","year":"2021","unstructured":"Riedl MA, Craig TJ, Banerji A, et al. Physician and patient perspectives on the management of hereditary angioedema: a survey on treatment burden and needs. Allergy Asthma Proc. 2021;42:S17-25.","journal-title":"Allergy Asthma Proc"},{"key":"3790_CR77","unstructured":"Friedhoff S, Khatami H, Cohen T, Tobin AE. People living with hereditary angioedema (HAE) prioritize attack-free status as a target for therapeutic efficacy. https:\/\/astriatx.com\/wp-content\/uploads\/2023\/07\/HAEA-Poster-Layout_For-Print.pdf. Accessed April 16, 2026."},{"key":"3790_CR78","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.anai.2025.12.011","volume":"136","author":"C Olson","year":"2026","unstructured":"Olson C, Lionetti M, Poulos C, et al. Long-term prophylactic treatment preferences and willingness to switch therapy in individuals with hereditary angioedema. Ann Allergy Asthma Immunol. 2026;136:322\u201332.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3790_CR79","unstructured":"US Food and Drug Administration. Center for biologics evaluation and research. The voice of the patient \u2013 hereditary angioedema. May 2018. https:\/\/www.fda.gov\/media\/113509\/download. Accessed April 16, 2026."},{"key":"3790_CR80","doi-asserted-by":"publisher","first-page":"406","DOI":"10.2500\/aap.2022.43.220046","volume":"43","author":"L Bouillet","year":"2022","unstructured":"Bouillet L, Fain O, Armengol G, et al. Long-term prophylaxis in hereditary angioedema management: current practices in France and unmet needs. Allergy Asthma Proc. 2022;43:406\u201312.","journal-title":"Allergy Asthma Proc"},{"key":"3790_CR81","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1016\/j.jaip.2023.04.017","volume":"11","author":"SD Betschel","year":"2023","unstructured":"Betschel SD, Banerji A, Busse PJ, Cohn DM, Magerl M. Hereditary angioedema: a review of the current and evolving treatment landscape. J Allergy Clin Immunol Pract. 2023;11:2315\u201325.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"3790_CR82","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/futurepharmacol4010005","volume":"4","author":"B Covella","year":"2024","unstructured":"Covella B, Giliberti M, Montinaro A, Rossi L, Montinaro V. Hereditary angioedema: novel molecules for treatment of acute attacks and long-term prophylaxis. Future Pharmacol. 2024;4:41\u201353.","journal-title":"Future Pharmacol"},{"key":"3790_CR83","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s40271-025-00798-8","volume":"19","author":"KF Villa","year":"2026","unstructured":"Villa KF, Mansfield C, Yarlas A, et al. Patient preferences for long-term prophylactic treatment in hereditary angioedema: a discrete-choice experiment. Patient (Auckl). 2026;19:481\u201395.","journal-title":"Patient (Auckl)"},{"key":"3790_CR84","first-page":"1512","volume":"23","author":"A Recke","year":"2025","unstructured":"Recke A. Status quo and future developments in the diagnosis and treatment of hereditary angioedema. J Dtsch Dermatol Ges. 2025;23:1512\u201325.","journal-title":"J Dtsch Dermatol Ges"},{"key":"3790_CR85","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2500\/aap.2010.31.3394","volume":"31","author":"WR Lumry","year":"2010","unstructured":"Lumry WR, Castaldo AJ, Vernon MK, Blaustein MB, Wilson DA, Horn PT. The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc. 2010;31:407\u201314.","journal-title":"Allergy Asthma Proc"},{"key":"3790_CR86","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01717-4","volume":"16","author":"J Mendivil","year":"2021","unstructured":"Mendivil J, Murphy R, de la Cruz M, et al. Clinical characteristics and burden of illness in patients with hereditary angioedema: findings from a multinational patient survey. Orphanet J Rare Dis. 2021;16:94.","journal-title":"Orphanet J Rare Dis"},{"key":"3790_CR87","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-025-04134-z","volume":"21","author":"M Watt","year":"2026","unstructured":"Watt M, Martinez-Saguer I, Simon A, et al. Burden of disease in adult patients with hereditary angioedema: results from a multinational survey. Orphanet J Rare Dis. 2026;21:70.","journal-title":"Orphanet J Rare Dis"},{"key":"3790_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2023.100758","volume":"16","author":"HJ Chong-Neto","year":"2023","unstructured":"Chong-Neto HJ. A narrative review of recent literature of the quality of life in hereditary angioedema patients. World Allergy Organ J. 2023;16:100758.","journal-title":"World Allergy Organ J"},{"key":"3790_CR89","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03265-z","volume":"19","author":"X Guan","year":"2024","unstructured":"Guan X, Sheng Y, Liu S, He M, Chen T, Zhi Y. Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review. Orphanet J Rare Dis. 2024;19:256.","journal-title":"Orphanet J Rare Dis"},{"key":"3790_CR90","doi-asserted-by":"publisher","first-page":"398","DOI":"10.2500\/aap.2025.46.250048","volume":"46","author":"DS Levy","year":"2025","unstructured":"Levy DS, Nagase FI, Cheung A, Rodeberg DA, Manning ME. Quality of life and burden of disease in patients with hereditary angioedema and their caregivers. Allergy Asthma Proc. 2025;46:398\u2013405.","journal-title":"Allergy Asthma Proc"},{"key":"3790_CR91","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2018.33.e213","volume":"33","author":"HS Kim","year":"2018","unstructured":"Kim HS, Lee S, Kim JH. Real-world evidence versus randomized controlled trial: clinical research based on electronic medical records. J Korean Med Sci. 2018;33:e213.","journal-title":"J Korean Med Sci"},{"issue":"1","key":"3790_CR92","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1186\/s13023-025-03739-8","volume":"20","author":"T Buttgereit","year":"2025","unstructured":"Buttgereit T, Aulenbacher F, Adatia A, et al. Unmet needs in hereditary angioedema: an international survey of physicians. Orphanet J Rare Dis. 2025;20:383.","journal-title":"Orphanet J Rare Dis"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03790-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03790-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03790-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:03:02Z","timestamp":1790640182000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03790-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":92,"alternative-id":["3790"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03790-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"8 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"John Anderson: Speaker bureau member for CSL Behring, Ionis, KalVista, Pharming, and Takeda; consulting fees from and clinical trial investigator for Astria, BioCryst, CSL Behring, Intellia, Ionis, KalVista, Pharming, Pharvaris, and Takeda. Laurence Bouillet: Consulted\/served as speaker for, engaged in research and educational projects with, or accepted travel grants from BioCryst, Blueprint, CSL Behring, GSK, KalVista, Novartis, Pharvaris, and Takeda. Paula J. Busse: Research support from and served on advisory boards for ADARx, BioCryst, CSL Behring, KalVista, Intellia, and Takeda; consultant for Astria, Ionis, and Pharvaris. Teresa Caballero: Member of advisory boards for Astria, BioCryst, CSL Behring, Intellia, Ionis, KalVista, Novartis, Pharming, Pharvaris, and Takeda; speaker bureau member for BioCryst, CSL Behring, Novartis, Otsuka, Pharming, Pharvaris, Sanofi, and Takeda; grants from CSL Behring and Takeda; funding to attend conferences\/educational events from BioCryst, CSL Behring, Novartis, Otsuka, and Takeda; clinical trial\/registry investigator for BioCryst, CSL Behring, KalVista, Novartis, Pharming, Pharvaris, and Takeda; researcher from the IdiPAZ program for promoting research activities. Mar Guilarte: Honoraria for educational purposes from CSL Behring, Novartis, and Takeda; participated in advisory boards organized by CSL Behring, Novartis, and Takeda; funding to attend conferences and educational events from CSL Behring, Novartis, Pharming, and Takeda; clinical trial\/registry investigator for BioCryst, CSL Behring, Novartis, Pharming, Pharvaris, and Takeda. Michihiro Hide: Personal fees from Argo Biopharma, Astria, BioCryst, CSL Behring, Intellia, Kaken, KalVista, Otsuka, Pharvaris, Takeda, and Torii. Ram\u00f3n Lleonart: Speaker\/consultancy fees from and\/or participated in advisory boards for BioCryst, CSL Behring, Novartis, Pharming, and Takeda; clinical trial\/registry investigator for BioCryst, Ionis, KalVista, Pharvaris, and Takeda. William R. Lumry: Consulted for, acted as speaker for, or collaborated in research with AstraZeneca, Astria, BioCryst, BioMarin, CSL Behring, Fresenius-Kabi, GSK, Grifols, Intellia, Ionis, KalVista, Magellan, Optinose, Pharming, Pharvaris, Regeneron, Sanofi, Takeda, and Teva. Markus Magerl: Research grant support and\/or speaker\/consultancy fees from or is\/was investigator in clinical studies for Argo, Astria, BioCryst, CSL Behring, Intellia, KalVista, Octapharma, Otsuka, Pharvaris, and Takeda. Marc A. Riedl: Research grant support, consultancy fees, speaker fees, and\/or clinical trial fees from ADARx, Astria, BioCryst, BioMarin, Celldex, CSL Behring, Cycle Pharma, Grifols, Intellia, Ionis, KalVista, Novartis, Pharming, Pharvaris, Sanofi-Regeneron, and Takeda. Patrick F.K. Yong: Fees\/grants for conference attendance, consulting, and\/or speaking from Astria, BioCryst, CSL Behring, KalVista, Pharming, Pharvaris, and Takeda. Andrea Zanichelli: Speaker\/consultancy fees from Astria, BioCryst, CSL Behring, Intellia, KalVista, Otsuka, Pharming, Pharvaris, and Takeda. Hannah Connolly: Employee of Adelphi Real World. Maggie Chen: Employee of Pharvaris Inc. and holds stocks in Pharvaris. Joan Mendivil: Employee of Pharvaris GmbH and holds stocks in Pharvaris.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involved a retrospective analysis of fully anonymized, non-interventional survey data. As the data were de-identified and gathered in a manner that did not allow for the identification of participants, this study was exempt from institutional review board approval. Patients were not involved in the design, conduct, reporting, or dissemination plans of this research.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}